ESPE Abstracts

Background: Few studies have investigated the long-term effects of gonadotropin releasing hormone (GnRH) agonist treatment on reproductive function.

Objective and hypotheses: We assessed ovarian function by analyzing serum anti-mullerian hormone (AMH) levels in central precocious puberty (CPP) girls according to GnRH agonist-treatment timing.

Method: Our study included 505 CPP girls subdivided into five groups based on the timing of GnRH agonist treatment: before treatment (n=98), 3 months after initiation (n=103), 12 months after initiation (n=101), 24 months after initiation (n=101), and 6 months after discontinuation (n=102). We compared serum AMH levels with 100 bone age-matched controls (before treatment; n=55, after discontinuation; n=45).

Results: At baseline, mean AMH level in CPP girls was 5.9±3.6 ng/ml. AMH levels decreased to 4.7±3.2 ng/ml after 3 months of GnRH agonist treatment, and recovered after 12 months of treatment. Six months after discontinuation, AMH levels were similar to pre-treatment levels. Before and after GnRH agonist treatment, AMH levels were similar to those of bone age-matched controls.

Conclusion: In precocious puberty girls, AMH levels according to the timing of GnRH agonist were all within the normal reference range. Our study suggested that there are no adverse effects of GnRH agonist treatment on reproductive function.